Vtv Therapeutics Inc., of High Point, N.C., completed patient enrollment in the company's AGATA (Add Glucokinase Activator to Target A1c) study, a phase IIb trial assessing the efficacy and safety of TTP399 in patients with type 2 diabetes. TTP399 is an oral, liver-selective glucokinase activator with first-in-class potential, the firm said. (See BioWorld Today, June 17, 2015.)